Fate Therapeutics (FATE) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
- Serbia's Vucic concedes defeat to student led movement in parliamentary election
Cowen Sees High Probability of Positive Data ASH at from Fate Therapeutics (FATE)
November 4, 2015 7:12 AM ESTCowen analyst Boris Peaker reiterated an Outperform rating on Fate Therapeutics (NASDAQ: FATE) and sees high probability of positive data at ASH.
Peaker commented, "Fate provided a pipeline update on its 3Q15 call as well as an overview of its... More



